Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
With reference to the stock exchange notice of 13th of January 2025 regarding new financing via a convertible loan. A group of investors, which participated in the investor consortium contributing to the convertible loan of total NOK 15 million, has exercised their right to convert the outstanding debt into shares. Debt that will be converted amount to NOK 3 million. The conversion price is set at a range of NOK 2,24 to NOK 2,29 per share based on the received conversion notices.
The Board of Directors will issue the shares, pursuant to authorization granted by the Company's General Meeting on 26th April 2024. Following the capital increase, the Company's shares outstanding will be 26.689.343 shares.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.